Some authors suggest that the serum carbohydrate antigen 19-9 (CA 19-9) may be a selection criterion for BR-PDAC resection after primary chemotherapy.[10] Similarly, we found that CA 19-9 levels before NAT were lower in the resection group than in the progression group, although not statistically significant.[11] Other authors suggest that a lower Eastern Cooperative Oncology Group performance status and tumor location in the pancreatic neck have higher resection possibilities,[12] whereas BR-PDACs with significant vascular contact have a worse prognosis.[13–15]. This evidence concerns the gene BRD2 and neoplasm.